|Elimination half-life||26-42 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||308.331 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Roquinimex has been investigated as a treatment for some cancers (including as adjuvant therapy after bone marrow transplantation in acute leukemia) and autoimmune diseases, such as multiple sclerosis and recent-onset type I diabetes. Several trials have been terminated due to serious cardiovascular toxicity.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|